2401 4TH AVE., SEATTLE, WA
Provides a 1Q26 Business Update; RAINIER on Track for 2026 Completion and Phase 2 Dose Selection
Reports 87% Clinical Benefit and 81% Remission in 31 Evaluable Frontline AML Patients Through Cohort 5, Substantially Outperforming Benchmark; RAINIER on Track for 2026 Completion and Phase 2 Dose Selection
Delivers Compelling 86% Clinical Benefit Rate and No CRS as Evaluable AML Patient Data increases by Nearly 50%
Stockholder Vote Results from Aptevo Therapeutics Special Meeting
Announces Executive Leadership Transitions to Support Next Phase of Growth
Secures $60 Million Equity Line of Credit to Support Multispecific Portfolio Advancement, Increase Strategic Optionality
Aptevo Therapeutics Inc. Approves Reverse Stock Split Amendment
Highlights Compelling Safety and Strong Remission Rates for Mipletamig in Frontline AML at ASH 2025
Q1
Q3
Q2
FY 2023
Prospectus filed pursuant to Rule 424(b)(4)
Effectiveness Notice
S-1
Definitive Proxy Statement
PRE 14A
Amended Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Initial Statement of Beneficial Ownership
Correspondence
Submission Upload